Uruguay

Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.

Latin American countries are continuing to pursue a strategy of jointly negotiating medicine prices to get a better deal on expensive medicines. However, manufacturers have expressed doubt that this is the best way forward.

Countries in South America have negotiated lower prices for the immunosuppressant tacrolimus and have their sights on high-cost oncology treatments. However, they have slammed companies selling new hepatitis C treatments for their inflexibility.

The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

Several countries in Asia are set to see the availability of additional vaccines for the prevention of some of the most common bacterial diseases in the region, by way of an alliance between a new European venture and a Cuban scientific research institute.

OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

Agency staff involved in medical countermeasure drug development and coordination of emergency activities will move into CDER director’s office, which also now houses the drug shortages program.

Agency staff involved in medical countermeasure drug development and coordination of emergency activities will move into CDER director’s office, which also now houses the drug shortages program.

Recalls reported by FDA for OTC drugs, nutritionals and personal care products.

Recalls reported by FDA for OTC drugs, nutritionals and personal care products.

OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

Dekkers gives Bayer two more years; Hilmas joins NPA; Hobbs directs Rainbow Light science; McSweeney starts at FTC; Bayer’s Mann takes WMSI chair; Archambault leads Ropack development.

Dekkers gives Bayer two more years; Hilmas joins NPA; Hobbs directs Rainbow Light science; McSweeney starts at FTC; Bayer’s Mann takes WMSI chair; Archambault leads Ropack development.